Return to search results.
Complete title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
|Research Study Number||2723.00|
|Principal Investigator||Bill Bensinger, MD|
Research Study Description
-- To establish the maximum tolerated dose (MTD) of oprozomib administered orally in combination with lenalidomide and dexamethasone
- Phase 2:
-- To estimate the overall response rate (ORR) and complete response rate (CRR)
- Secondary Objectives:
-- * To evaluate the safety and tolerability of oprozomib administered in combination with lenalidomide and dexamethasone
-- * To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with lenalidomide and dexamethasone
-- * To estimate the duration of response (DOR)
-- * To estimate progression-free survival (PFS)
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Lymphoproliferative Disease; Multiple Myeloma (MM)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.